Blood Res.  2024;59:15. 10.1007/s44313-024-00016-8.

What is new in acute myeloid leukemia classification?

• Park H

• KMID: 2562519
• DOI: http://doi.org/10.1007/s44313-024-00016-8

Abstract

Recently, the International Consensus Classification (ICC) and the ­5^th edition of the World Health Organization classification (WHO2022) introduced diagnostically similar yet distinct approaches, which has resulted in practical confusion. This review compares these classification systems for acute myeloid leukemia (AML), building up on the revised 4th edition of WHO (WHO2016). Both classifications retain recurrent genetic abnormalities as a primary consideration. However, they differ in terms of blast threshold. The ICC mandates a minimum of 10% blasts in the bone marrow or peripheral blood, whereas the WHO2022 does not specify a blast cut-off. AML with BCR::ABL1 requires > 20% blast count in both classifications. In WHO2022, AML with CEBPA mutation requires > 20% blasts. TP53 mutation, a new entity is exclusive to ICC, diagnosed with > 20% blasts and variant allele frequency > 10%. AML with myelodysplasiarelated changes is defined by cytogenetic or gene mutation-based criteria, not morphological dysplasia. Eight genes were common to both groups: ASXL1, BCOR, EZH2, SF3B1, SRSF2, STAG2, U2AF1, and ZRSR2. An additional gene, RUNX1, was included in the ICC classification. AML cases defined by differentiation (WHO2022) and AML not otherwise specified (ICC) are categorized as lacking specific defining genetic abnormalities, WHO2022 labels this as a myeloid neoplasm post cytotoxic therapy (MN-pCT), described as an appendix after specific diagnosis. Similarly, in ICC, it can be described as “therapy-related”, without a separate AML category.

Keyword

Acute myeloid leukemia; International Consensus Classification; WHO classification

Reference

1. Appelbaum FR. 2023; WHO, what, when, where, and why: new classification systems for acute myeloid leukemia and their impact on clinical practice. Best Pract Res Clin Haematol. 36:101518. DOI: 10.1016/j.beha.2023.101518. PMID: 38092471.

2. Falini B, Martelli MP. 2023; Comparison of the International Consensus and 5th WHO edition classifications of adult myelodysplastic syndromes and acute myeloid leukemia. Am J Hematol. 98:481–92. DOI: 10.1002/ajh.26812. PMID: 36606297.

3. Shallis RM, Daver N, Altman JK, et al. 2023; Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts. Lancet Haematol. 10:e767–76. DOI: 10.1016/S2352-3026(23)00159-X. PMID: 37572683.

4. Weinberg OK, Porwit A, Orazi A, et al. 2023; The International Consensus Classification of acute myeloid leukemia. Virchows Arch. 482:27–37. DOI: 10.1007/s00428-022-03430-4. PMID: 36264379.

5. Arber DA, Orazi A, Hasserjian RP, et al. 2022; International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 140:1200–28. DOI: 10.1182/blood.2022015850. PMID: 35767897. PMCID: PMC9479031.

6. Bennett JM, Catovsky D, Daniel MT, et al. 1976; Proposals for the classification of the acute leukaemias French-American-British (FAB) co-operative group. Br J Haematol. 33:451–8. DOI: 10.1111/j.1365-2141.1976.tb03563.x. PMID: 188440.

7. Jaffe ES, Harris NL, Stein H, Vardiman JW. 2001. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. 3rd ed. IARC Press;Lyon, France: DOI: 10.1093/annonc/mdf146.

8. Swerdlow SH, Campo E, Harris NL, editors. 2008. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. IARC Press;Lyon, France: DOI: 10.53347/rid-9250.

9. Arber DA, Orazi A, Hasserjian R, et al. 2016; The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 127:2391–405. DOI: 10.1182/blood-2016-03-643544. PMID: 27069254.

10. Khoury JD, Solary E, Abla O, et al. 2022; The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 36:1703–19. DOI: 10.1038/s41375-022-01613-1. PMID: 35732831. PMCID: PMC9252913.

11. Falini B, Brunetti L, Sportoletti P, Martelli MP. 2020; NPM1-mutated acute myeloid leukemia: from bench to bedside. Blood. 136:1707–21. DOI: 10.1182/blood.2019004226. PMID: 32609823.

12. Hwang SM. 2020; Classification of acute myeloid leukemia. Blood Res. 55:S1–4. DOI: 10.5045/br.2020.S001. PMID: 32719169. PMCID: PMC7386892.

13. Falini B, Martelli MP, Bolli N, et al. 2011; Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity? Blood. 117:1109–20. DOI: 10.1182/blood-2010-08-299990. PMID: 21030560.

14. Montalban-Bravo G, Kanagal-Shamanna R, Sasaki K, et al. 2019; NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy. Blood Adv. 3:922–33. DOI: 10.1182/bloodadvances.2018026989. PMID: 30902805. PMCID: PMC6436014.

15. Forghieri F, Nasillo V, Paolini A, et al. 2020; NPM1-mutated myeloid neoplasms with< 20% blasts: a really distinct clinico-pathologic entity? International J Mol Sci. 21:8975. DOI: 10.3390/ijms21238975. PMID: 33255988. PMCID: PMC7730332. PMID: cacc199de55c49faac8a61cb3744ae3a.

16. Su L, Shi Y-Y, Liu Z-Y, Gao S-J. 2022; Acute myeloid leukemia with CEBPA mutations: current progress and future directions. Front Oncol. 12:806137. DOI: 10.3389/fonc.2022.806137. PMID: 35178345. PMCID: PMC8844020. PMID: 3e34608a1c4c46e1b206a78d815c8a2a.

17. Snaddon J, Smith ML, Neat M, et al. 2003; Mutations of CEBPA in acute myeloid leukemia FAB types M1 and M2. Genes Chromosomes Cancer. 37:72–8. DOI: 10.1002/gcc.10185. PMID: 12661007.

18. Bernard E, Nannya Y, Hasserjian RP, et al. 2020; Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nat Med. 26:1549–56. DOI: 10.1038/s41591-020-1008-z. PMID: 32747829. PMCID: PMC8381722.

19. Bertrums EJ, Smith JL, Harmon L, et al. 2023; Comprehensive molecular and clinical characterization of NUP98 fusions in pediatric acute myeloid leukemia. Haematologica. 108:2044. DOI: 10.3324/haematol.2022.281653. PMID: 36815378. PMCID: PMC10388277.

20. Gao Y, Jia M, Mao Y, et al. 2022; Distinct mutation landscapes between acute myeloid leukemia with myelodysplasia-related changes and de novo acute myeloid leukemia. Am J Clin Pathol. 157:691–700. DOI: 10.1093/ajcp/aqab172. PMID: 34664628.

21. Tazi Y, Arango-Ossa JE, Zhou Y, et al. 2022; Unified classification and risk-stratification in acute myeloid leukemia. Nat Commun. 13:4622. DOI: 10.1038/s41467-022-32103-8. PMID: 35941135. PMCID: PMC9360033. PMID: f0c1b3c2c89c4431b1bfec535238074b.

22. Alexander TB, Orgel E. 2021; Mixed phenotype acute leukemia: current approaches to diagnosis and treatment. Curr Oncol Rep. 23:1–10. DOI: 10.1007/s11912-020-01010-w. PMID: 33544265.

23. Döhner H, Wei AH, Appelbaum FR, et al. 2022; Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 140:1345–77. DOI: 10.1182/blood.2022016867. PMID: 35797463.

24. Döhner H, Estey E, Grimwade D, et al. 2017; Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 129:424–47. DOI: 10.1182/blood-2016-08-733196. PMID: 27895058. PMCID: PMC5291965.

25. Kayser S, Hills RK, Langova R, et al. 2021; Characteristics and outcome of patients with acute myeloid leukaemia and t (8; 16)(p11; p13): results from an International Collaborative Study. Br J Haematol. 192:832–42. DOI: 10.1111/bjh.17336. PMID: 33529373.

26. Ottema S, Mulet-Lazaro R, Beverloo HB, et al. 2020; Atypical 3q26/MECOM rearrangements genocopy inv (3)/t (3; 3) in acute myeloid leukemia. Blood. 136:224–34. DOI: 10.1182/blood.2019003701. PMID: 32219447.

27. Short NJ, Tallman MS, Pollyea DA, Ravandi F, Kantarjian H. 2021; Optimizing risk stratification in acute myeloid leukemia: dynamic models for a dynamic therapeutic landscape. J Clin Oncol. 39:2535. DOI: 10.1200/JCO.21.00067. PMID: 34043455. PMCID: PMC9851692.

28. Ahn J-S, Kim H-J. 2022; FLT3 mutations in acute myeloid leukemia: a review focusing on clinically applicable drugs. Blood Res. 57(S1):32–3. DOI: 10.5045/br.2022.2022017. PMID: 35483923. PMCID: PMC9057665.

29. Kim D-S, Byun J-M, Shin D-Y, et al. 2023; Concomitant ruxolitinib with cytarabine-bassed induction chemotherapy in secondary acute meyloid leukemia evolving from myeloproliferative neoplasm. Blood Res. 58(3):155–7. DOI: 10.5045/br.2023.2023136. PMID: 37621072. PMCID: PMC10548284.